VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
Our stock is traded on the NASDAQ under the symbol VBIV.
No, you will need to contact a licensed stock broker or use an online trading account.
Through a licensed stock broker or by using an online trading account.
Through your brokerage account or by contacting our transfer agent.
Variation Biotechnologies Inc. was federally incorporated in Canada on August 24, 2001; Variation Biotechnologies (US), Inc. was incorporated in Delaware on December 18, 2006.
250 Royall Street
Canton, MA 02021
Telephone: (781) 575-2000
111 Wood Avenue South
Iselin, NJ 08830-2700
Telephone: (732) 243-7000
U.S. Legal Counsel
Haynes Boone LLP
30 Rockefeller Plaza, 26th Floor
New York, NY 10112
Canadian Legal Counsel
5300 Commerce Court West
199 Bay Street
Toronto, Ontario M5L 1B9
325414 Vaccines (i.e., bacterial, virus) manufacturing
2836 Biologics Products, except diagnostics substances
Email us at IR@vbivaccines.com.